Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• The T315I mutation in BCR-ABL1 confers resistance to all first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
• Developing effective treatment strategies for CML patients with the T315I mutation remains a significant clinical challenge.

Observation:

• This report details a case of a chronic myeloid leukemia patient with both T315I and E255V mutations in BCR-ABL1.
• The patient was treated with a combination of dasatinib and interferon-alfa (IFN-α).

Findings:

• The patient successfully achieved a deep molecular response (DMR).
• This outcome suggests that the combination of dasatinib and IFN-α can be effective in managing CML with the T315I mutation.

Implications:

• This case adds to the limited evidence supporting the efficacy of dasatinib plus IFN-α for T315I-positive CML.
• This combination therapy may represent a viable treatment option for CML patients who are refractory to standard TKIs due to the T315I mutation.